Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review
Author:
Funder
Celgene International Sàrl
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference45 articles.
1. World Health Organization. Breast cancer: prevention and control. Breast cancer burden. Available from: [accessed 12.06.15].
2. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2012
3. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality;Vera-Llonch;BMC Cancer,2011
4. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer;Lin;Breast,2013
5. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials;Kiely;J Clin Oncol,2011
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis;Journal of Oncology;2023-02-08
2. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer;Cancer Treatment Reviews;2022-12
3. Longitudinal efficacy and safety of capecitabine and cyclophosphamide as early-line treatment in patients with metastatic breast cancer: A prospective cohort study by the Kyushu Breast Cancer Study Group, Japan.;Annals of Cancer Research and Therapy;2022-01-31
4. Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single‑center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database;Oncology Letters;2020-08-05
5. Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer;Acta Oncologica;2020-03-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3